Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. - Wikidata - wikimedia - TriplyDB

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

http://www.wikidata.org/entity/Q33423816

about

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Therapeutic options in peripheral T cell lymphoma The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis Epigenetic treatment of solid tumours: a review of clinical trials Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China Epigenetics in Cancer: A Hematological Perspective T-cell lymphomas, a challenging disease: types, treatments, and future.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma Epigenetics in cancer stem cells.THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors Chimeric antigen receptor T-cell therapies for lymphoma.Therapeutic Options for Aggressive T-Cell Lymphomas.Breakthrough therapies in B-cell non-Hodgkin lymphoma.The discovery and development of romidepsin for the treatment of T-cell lymphoma.Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Panobinostat for the management of multiple myeloma.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Targeting histone deacetylases in T-cell lymphoma.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Chidamide in the treatment of peripheral T-cell lymphoma A chemical probe toolbox for dissecting the cancer epigenome.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

P2860

Q26744080-DD9F0359-E1D8-42D2-A11A-4243EF2EFC3F Q26746934-0CC29804-7904-46F1-8012-B476006666E9 Q26748857-55B67DBD-7A07-401A-9F05-574D6ADA4E86 Q26771181-A9C18FF9-767A-496E-ACEA-A36DA7CFA709 Q26773803-9E3D7E3F-79C3-4441-9294-A4D423B26704 Q28070073-3D864DE7-6DAC-479A-9D26-CC3D802A19E7 Q28077082-6277B49C-3251-4C72-9D17-6BD865EA65B8 Q30244553-C4CE07D6-EA20-4128-8E36-0C24DB4A1B62 Q33431457-EEC2A866-4DDC-42A7-B6C1-922A3CD6A3AA Q33436867-85C4C03C-41BC-4FFE-B316-5F7E925B2728 Q33438732-1533C85E-FBBF-4D6B-8D35-8BBE291C2588 Q33438820-B86E0E61-08F8-4717-9716-266C9EC97D75 Q36671582-437D3F5A-ED8C-4E28-82B7-B8B0D5874541 Q37579991-24074A2E-2D1A-45E9-A6DF-8E6AE036A7BC Q37609238-4B4ABC0C-1ECE-4CD9-96D6-865D194348DA Q37618640-270B1853-DFDE-4F77-999C-A53C475E6C8D Q37622508-48EC41F0-9BEF-4961-8785-98DEE67E7DCE Q38600697-0D32279D-DC26-4667-85D5-5F96AD8C55F9 Q38675843-1AFC83F9-EDEF-4D61-9DDE-B8137287CA35 Q38708600-19278EB1-2EF8-4C14-8FEE-87C005FA102E Q38713744-E9F87117-08BC-4C5E-890F-1D73BF903684 Q38725415-D241CAFF-B909-40B4-8152-83F9EC83F73D Q38765451-7E57699E-0262-4926-83DA-E60E9DEC2B30 Q38780407-28D6177E-47E6-48B5-B409-79F8735D5E19 Q38782072-22728776-A038-4B57-8C87-BCC08CD63586 Q38806260-E95C9D86-FAA7-4568-9D39-7F4528E37D91 Q38838643-0BEAE136-3A0C-4977-A00D-A6BAD8945F98 Q38843100-8CE96D60-EAC6-46C7-A733-07174D635330 Q38984578-3302ED5C-C720-4063-ABB6-779A0F4E906E Q38998630-A06B0DEE-3FDD-4025-AA5F-CF00291A6A14 Q39055861-EE5B377E-D9EA-4E26-A956-BD3E2066D228 Q39063866-B9FC9561-D069-469C-9D83-8F3340E4FEC8 Q39091822-391AEE55-29B8-45B2-B937-4853CA1D3031 Q39110404-FB147632-F5A9-42AD-9576-AA864D93E43D Q39147132-13CE36D4-E871-4C54-8941-1E65E26F3013 Q39287526-C6E7AC10-B9F8-44A1-A1DD-B4F0000062A6 Q40144116-A29CDCB0-F9ED-496D-B74A-4F99A62EF6F2 Q41064275-5A88C324-F8EA-4060-ADAB-E10CE226A9E3 Q41556725-3626D58F-5877-422A-A449-1D2D6969922A Q42388539-146AC5A2-BC7E-4797-A524-269615992B90

P2860

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

http://www.wikidata.org/entity/Q33423816

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@ast

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@en

type

label

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@ast

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@en

prefLabel

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@ast

Belinostat in Patients With Re ...... hase II BELIEF (CLN-19) Study.

@en

P1433

Q33423816-A0656680-BCCC-4895-9E16-96A7BD377851

P1476

Q33423816-5DC57BFB-519A-4439-9078-DB93533533CF

P2093

Q33423816-061A75F7-3542-4960-A20E-9B63A7E15C75

Q33423816-07EFA25C-8656-4987-B8E4-CAB1C9551525

Q33423816-09EC9C0B-479D-4472-982F-212AFB85DE31

Q33423816-28EE5743-9263-4045-AAE6-01D6A544080D

Q33423816-3789134E-8772-499B-862A-9A8B7B4D9047

Q33423816-664E792C-A1D9-4173-B4A0-44FCA925E03D

Q33423816-6F0D0E22-813C-4ED4-80FE-E9EEFAD0E2B4

Q33423816-71ECBAAA-A914-47BC-A11E-E50FC00D1145

Q33423816-7B45A088-749D-41EF-B69E-D57EEFE9F2DD

Q33423816-909CEB4E-5163-44AB-ACCE-9FC7DDB8E3C8

P2860

Q33423816-0B782C03-A05E-4F9B-8674-A1A280C3B719

Q33423816-119F0797-0331-4854-BDDE-27E293E88CA7

Q33423816-13817263-9EE8-466B-8D23-255AEE72651F

Q33423816-25DA92BF-757D-4077-B509-CC35E6165CE5

Q33423816-280F58B4-447F-4678-ABE1-0BCB74D288CE

Q33423816-30AA2DE8-F0DE-4537-8354-E87E1BFCCE26

Q33423816-312199D2-9DEC-4CE5-89AD-306B8D3F2E1C

Q33423816-3CD8CCB3-6C24-445F-A0C2-D3CB64DB83AA

Q33423816-3D20D43B-279D-49C4-809C-916C3C3ABE7E

Q33423816-4574F96E-A6EB-4D01-9D48-7BC6BB9E776F

P304

Q33423816-83D861C2-795C-4735-9B41-46D4171F23B5

P31

Q33423816-209AFA8E-6AE9-4C43-94DA-CCA9CD668B65

P356

Q33423816-6B411D90-EE7D-4A22-B91E-80DB7F495168

P407

Q33423816-89916B38-F5C4-4E0F-86C9-5BB998F3B561

P433

Q33423816-F115E492-AA89-4EE5-92DB-AAAB9AD857B5

P478

Q33423816-6A3B1227-5F2A-4A7E-A268-C7D45493A437

P50

Q33423816-2CABCCF4-C70D-416B-B02F-89C27243D1F6

Q33423816-8480FE52-8998-4ACD-A90E-1D274C10AE33

Q33423816-A4D10A05-D8EB-4DFF-86CF-DC9BDBDA0E9C

P577

Q33423816-D5DC6491-955A-4E61-80C8-8DD3D3D22304

P698

Q33423816-76E7F3B3-A9CE-4876-98B5-B8C959826E70

P921

Q33423816-61472D76-6E03-42C9-8AC2-7E748FAB5134

P932

Q33423816-3CFD67BB-B72F-42B9-A379-B358DABC9E8D

P356

JCO.2014.59.2782

P1433

Journal of Clinical Oncology

P1476

Belinostat in Patients With Re ...... Phase II BELIEF (CLN-19) Study

@en

P2093

Achiel Van Hoof

http://www.w3.org/2001/XMLSchema#string

Andrei Shustov

http://www.w3.org/2001/XMLSchema#string

Francine Foss

http://www.w3.org/2001/XMLSchema#string

Gajanan Bhat

http://www.w3.org/2001/XMLSchema#string

Georg Hess

http://www.w3.org/2001/XMLSchema#string

Jeannette Doorduijn

http://www.w3.org/2001/XMLSchema#string

Kerry Savage

http://www.w3.org/2001/XMLSchema#string

Lee F Allen

http://www.w3.org/2001/XMLSchema#string

Mi Rim Choi

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

P2860

The aggressive peripheral T-cell lymphomas: 2013

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

P304

2492-2499

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.59.2782

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Wojciech Jurczak

P577

2015-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26101246

http://www.w3.org/2001/XMLSchema#string

P921

P932

5087312

http://www.w3.org/2001/XMLSchema#string